How Does Potaba Work? Mechanism of Action Explained in Plain English

Potaba (potassium aminobenzoate) is prescribed for diseases that cause abnormal tissue hardening — a process called fibrosis. But how does a B-vitamin derivative actually stop or slow the formation of fibrous scar tissue? This article explains the mechanism of action of Potaba in plain language, without requiring a medical degree to understand.

What Is Fibrosis and Why Is It a Problem?

Fibrosis is the excessive buildup of fibrous connective tissue in an organ or tissue. Think of it as the body's wound-healing system going into overdrive — instead of repairing a wound normally and stopping, the body keeps laying down collagen and scar tissue. Over time, this buildup hardens and stiffens the affected tissue, reducing its normal function.

In Peyronie's disease, fibrosis occurs inside the penis (in the tunica albuginea), forming plaques that cause curvature and pain. In scleroderma, fibrosis affects the skin and internal organs. In morphea and dermatomyositis, fibrosis occurs in the skin and muscles.

How Does Potaba Fight Fibrosis? Three Key Mechanisms

Potaba is thought to reduce fibrosis through several interrelated mechanisms:

Mechanism 1: Increasing Oxygen Uptake in Tissues

One of the oldest proposed mechanisms for Potaba's antifibrotic action is that it increases oxygen uptake at the tissue level. The theory is that higher local oxygen levels improve cellular metabolism, which in turn reduces the conditions that favor fibroblast overactivity and excessive collagen deposition.

Think of it this way: tissues that are starved of oxygen are more prone to abnormal healing. By improving oxygen availability, Potaba may help the tissue heal more normally, reducing the drive toward fibrosis.

Mechanism 2: Inhibiting Fibroblasts and Reducing Collagen Production

Fibroblasts are the cells responsible for producing collagen and other extracellular matrix proteins. In fibrotic diseases, fibroblasts become overactive — they produce far more collagen than normal, leading to tissue hardening.

Potaba is thought to inhibit fibroblast activity by interfering with their secretion of glycosaminoglycans — the chemical scaffolding that supports collagen accumulation. By reducing this scaffolding, Potaba makes it harder for collagen to build up in the affected tissue.

Mechanism 3: Modulating Serotonin and Monoamine Oxidase Activity

This is the most complex mechanism — but here's the plain-English version:

Serotonin (yes, the same molecule associated with mood) plays a role in wound healing and fibrosis — elevated serotonin in local tissues can drive fibroblast activity and collagen production. Monoamine oxidase (MAO) is an enzyme that breaks down serotonin. Potaba is believed to increase MAO activity, which breaks down more serotonin. Lower local serotonin levels mean less stimulation of fibroblasts — which means less collagen, less scarring, and potentially less fibrosis.

The Anti-Inflammatory Component

Inflammation is closely linked to fibrosis — it's often the initial trigger that kicks off the abnormal healing response. Potaba also has anti-inflammatory properties, which may help interrupt the fibrosis process at an earlier stage. By reducing inflammation in affected tissues, it may reduce the signals that tell fibroblasts to go into overdrive.

How Long Does It Take for Potaba to Work?

Because fibrosis is a slow process, reversing or slowing it is also slow. Most patients on Potaba don't notice significant changes for several months. In the landmark 2005 Peyronie's disease study, patients were treated for 12 months before outcomes were assessed. Improvement in plaque size was noted, but improvement in penile curvature was not observed even at 12 months.

Patience is essential when taking Potaba. The drug's effects are gradual, and the goal is often stabilization of disease progression rather than dramatic improvement. This is why your doctor may recommend monitoring over months rather than expecting quick results.

Is Potaba's Mechanism Fully Understood?

Honestly — not completely. Potaba was introduced decades ago, and while there is a plausible mechanistic framework, the full story of exactly how it modulates fibrosis in humans is not entirely worked out. This is one reason why clinical guideline bodies like the AUA don't strongly endorse it: the evidence base for both its mechanism and clinical efficacy is thinner than for newer antifibrotic agents.

To learn more about the practical aspects of taking Potaba — including dosage, how to take it, and who it's for — see What Is Potaba? Uses, Dosage, and What You Need to Know in 2026.

Before starting Potaba, also review Potaba Drug Interactions: What to Avoid and What to Tell Your Doctor to ensure safe use with your other medications.